Introduction
Prader ± Willi syndrome (PWS) was originally described less than 50 y ago, 1 although reference to children with characteristics of the syndrome are to be found in other literature previous to this. 2 Until relatively recently the diagnosis was made upon the clinical features as outlined by Holm, 3 which include severe muscular hypotonia in the neonatal period leading to feeding dif®culties and undernutrition, hypogonadism and later hyperphagia and obesity. Latterly the syndrome has been identi®ed as being associated with an interstitial deletion of the q11 ± 13 region on chromosome 15 . 4 In the majority of cases the deletion is in the paternally derived chromosome. In the remainder of cases there seems to be a failure to inherit the entire paternal chromosome and as a consequence both the chromosomes inherited are maternal, thus leading to maternal disomy.
The prevalence of the syndrome varies in the literature but a consensus view might be a ®gure of 1 in 10 000 births. The syndrome is an extremely debilitating disorder that in many cases places great stress on the families concerned. As an example of the magnitude of the population with the syndrome, it has been estimated that there are between 17 000 and 22 000 individuals in the USA with PWS. Thus, although a rare disorder, it is one of the 10 most common conditions seen at genetic clinics and the most common genetic cause of obesity. Some common features of the syndrome are shown in Table 1 . Although there are many and varied problems associated with the syndrome, during childhood and adolescence the major problem is profound and marked hyperphagia leading, in most cases, to massive and morbid obesity. Children and young adults with PWS therefore suffer many of the common effects of obesity and many die prematurely due to illness associated with excessive body weight.
A recent study 5 elegantly described the speci®c body composition found in the syndrome and noted that the distribution of body fat was similar to that found in classical isolated idiopathic growth hormone (GH) de®ciency. Moreover, the reduction of fat-free mass and increase in fat mass found in PWS is again a characteristic of long-term suboptimal GH secretion. These ®ndings, among others, have led to the consideration that a fundamental part of the syndrome itself is GH de®ciency and therefore exogenous GH administration might be of bene®t to children and young adults with PWS.
GH secretion in PWS
The normality or otherwise of GH secretion in PWS has been the subject of much debate in the literature over many years. Some studies found a large percentage of individuals had a blunted GH response to pharmacological stimulation, 6, 7 whilst others found the majority of their patients had apparently normal responses. 8 Some of these disparate ®ndings are undoubtedly due to the fact that many individuals with PWS are overweight or obese, a condition which is known, in itself, to reduce the response of GH secretion to pharmacological stimulation. 9 One study that successfully overcame this confounding factor was that of Angelo and colleagues, 6 who investigated GH secretion in obese and non-obese individuals with PWS. As might be expected the obese group showed blunted GH secretion but importantly this was mirrored in the non-obese group, with more than 50% of tested children showing blunted GH secretion. In order to more fully investigate GH secretion in PWS Thacker and colleagues 10 retrospectively analysed data from 16 children with PWS of which 12 were obese. L-dopa and arginine stimulation of the hypothalamus were used in the majority of cases. Four of the 16 children were GH suf®cient using a criteria of GH response of b 10 ngaml following the hypothalamic stimulation. The obvious inference to be drawn from these studies is that a hypothalamic dysfunction is responsible for the GH de®ciency in PWS.
Nevertheless, it is sometimes suggested that the response of GH secretion to non-pharmacological stimulation represents a more physiological investigation into proposed disturbances in secretory mechanism. Thus it has been found that in PWS the GH response to a dose of 1mgakg intravenous growth hormone releasing hormone (GHRH) was signi®-cantly less than that found in obese controls. 11 Moreover, the use of hexarelin, a synthetic hexapeptide with wellknown potent GH releasing activity, produced similar results, when in`simple obesity' hexarelin usually produces a marked GH response. This ®nding led to the conclusion that possibly individuals with PWS have what might be called a more servere pituitary GH de®ciency. Grugni and colleagues, 12 who also used GHRH and pyridostigmine (a cholinergic agonist that suppresses somatostatin release, by the hypothalamus and hence enhances GH release) to assess GH secretion in 22 children with PWS, mirrored such ®nd-ings. The GH response to GHRH and pyridostigmine was signi®cantly lower in children with PWS when compared with either short normal children or obese children.
The status of IGF-1 secretion in PWS has also been debated. If the reduced GH secretion often seen in PWS was a function of the obesity found in the syndrome one would expect to see elevated or at the least normal IGF-1 levels. This has been the case in some studies, 7 whilst in others blunted GH secretion and low IGF-1 levels have been reported. 6 The work of Thacker and colleagues 10 has made an important contribution in this area in that, as they state, they analysed GH and IGF-1 status with respect to weight for height indices. As has been previously mentioned, GH de®-ciency was diagnosed in 12 of their 16 patients and IGF-1 levels were normal in only one of those. All of the children with a normal weight for height were GH de®cient, suggesting a primary hypothalamic ± pituitary axis abnormality in the syndrome resulting-in low circulating IGF-1 levels. Whilst it would be wrong to make generalizations in this population, undoubtedly a large number of children and young adults with PWS have inadequate GH secretion and low levels of circulating IGF-1.
The effect of GH administration on body composition and linear growth
Whilst it has long been recognized, at least in theory, that several of the physiological characteristics of PWS might be improved by exogenous GH administration, it is only in the last few years that data has been forthcoming to test that hypothesis.
The metabolic effects of GH administration are well known. Primarily GH has an anabolic effect in children and adults. It has been well documented over a number of years that nitrogen retention increases very soon after GH administration in GH-de®cient individuals. 13 This increased nitrogen retention is a result of marked increases in protein synthesis, 14 which leads to an increase in the fat free mass of the individual. 15 Concurrently the marked lipolytic effect of GH causes a reduction in fat mass. 16 Nevertheless prior to 1997 there were only a few reports in the literature of the effect of exogenous GH on body composition or linear growth in children with PWS, most with very small sample sizes. For example, Lee and colleagues 17 in 1987 reported the results of giving GH to four children for periods of time ranging from 4 months to 3 y. Linear growth velocity (cmay) was shown to dramatically increase in three of the four cases, with only the eldest individual, with a bone age of 13 y, not responding signi®cantly during the GH treatment. No data were reported relating to changes in body composition.
Changes in both body weight and body mass index (BMI) were reported in six subjects receiving GH for 6 months by Angelo and colleagues 18 in 1990. During the period of GH administration weight gain slowed to an average of 1.4 kg compared with an average weight gain of 3.8 kg over the 6 months prior to treatment. Mean BMI reduced from 26.4 to 24.8 kgam 2 . These researchers concluded that their ®ndings con®rmed previous suggestions of neurosecretory GH de®-ciency in PWS and that there were possible bene®ts of GH therapy in the syndrome.
In an editorial published in 1993 19 it was argued that`no virtue goes with size'; size in this case relating to stature, and it was suggested that increasing an individual's height by, say, 7 ± 8 cm by GH administration did not necessarily warrant the potential side effects and, interestingly, the cost, being cited as US$15 000 ± 20 000 per year of treatment at that time. The editorial concluded, however, that while no virtue goes with size (stature) there was virtue in preventing or reducing the morbid obesity of the child with PWS, but the case for GH doing so was yet to be made.
Despite the few data available clinicians were coming under increasing pressure to prescribe GH for children with PWS on a routine basis. Many clinicians and scientists around the world felt more data were needed to support the ef®cacy or otherwise of GH treatment before widespread prescription could be considered. Almost simultaneously ®ve studies were begun in the USA, Germany, Switzerland, Scandinavia and the UK that aimed to provide such data. The US study, based in New York, evaluated the effect of 2 y of GH therapy in a cohort of 30 children with PWS aged between 2 and 16 y. 6 The treatment resulted in the mean height standard deviation score (SDS) changing from 72.2 to 70.8 over the study period. The authors also revealed that the response, at least in terms of linear growth, was rapid, with height velocity more than doubling in the ®rst 6 month period. Mean weight SDS also changed dramatically falling from approximately 3.5 to 2.1 over the 2 y period. There were no data provided on any changes in body composition.
The German study based in Essen 20 evaluated linear growth and body composition in a group of eight children receiving GH, in comparison with a control group of nine children, over a 1 y period. Signi®cant increases in linear growth were reported in the treatment group but no signi®cant changes in body weight or BMI were found.
In 1998 the results of the other three studies were published within a few months of each other detailing, in total, the response of some 66 children with PWS to GH administration.
The ®rst of these studies 21 examined the effect of 1 y of GH administration on 12 children with PWS. Over the 12 month period height velocity increased dramatically. Importantly, however, body weight (as measured as a standard deviation score) reduced, and there were signi®cant reductions in fat mass and increased levels of fat free mass.
The second of the studies 22 followed 25 children over a 6 month period of GH administration with changes in growth and body composition in the previous 6 months acting as a comparison. There was a signi®cant increase in linear growth velocity over the 6 months of treatment. Moreover, percentage body fat, as assessed via the use of stable isotopes to measure total body water, fell on average by nearly 8 percentage points. This study also used multiple regression to determine the in¯uencing factors on change in percentage body fatness in the 25 children. Out of sex, age, height, weight and percentage body fat at initiation of GH treatment only the latter signi®cantly predicted the response in body composition, with the children with the largest percentage body fat showing the greatest change in body composition.
The ®nal of the three studies 23 published in mid 1998, a collaboration between scientists in Stockholm and Copenhagen, evaluated changes in body composition over a 1 y period in a group of 15 children aged between 3 and 11 y with PWS receiving GH. Consistent with the ®ndings of the two other studies published in 1998, there was a signi®cant increase in height velocity and a major decrease of about 10 ± 15 percentage points in body fat as measured by both dual-energy X-ray absorptimetry (DXA) and bioelectrical impedance.
More data emerged from the USA in a recent paper published in 1999. 24 This comprehensive study evaluated the response to GH administration in a cohort of 35 children with PWS over a 12 month period. This study also included a smaller control group. Mean height SDS changed from 71.1 to 70.6 in the treatment group but remained virtually static in the control group, changing from 71.5 to 71.6. These changes are re¯ected in the mean growth velocity in the two groups, 10.0 cmay in the treatment group and 5.0 cmay in the control group. Body fat was assessed by DXA. The control group showed an increase in percentage body fat over the 12 month period, increasing, on average, from 42.6% to 45.8%. A dramatic reduction in body fat levels, from 46.3% to 38.4%, was found in the treatment group. This decrease in body fat was accompanied by a mean increase in fat-free mass of almost 20% (20.5 kg changing to 25.6 kg). This will lead to an increase in resting metabolic rate, in absolute terms, which will be of bene®t to the individual in relation to maintaining an appropriate energy balance.
The effect of GH administration on muscle capacity and endurance
The changes seen in body composition may not simply be anatomical but might have important physiological consequences for individuals with PWS. For example, in the study of Eiholzer and colleagues, 21 the authors measured`physical capability', ie an estimate of physical ®tness, and this was reported to have improved considerably. It is probable that this improvement was due in part to the effect of the administered GH, which acted to increase fat-free mass over the 12 month period. Muscle endurance and peak power were measured by a 30 s cycling test during which maximal effort is required by the subject. This test, the Wingate anaerobic test, is well documented and validated. Data obtained from four of the 12 subjects showed dramatic improvements. Mean peak power, when expressed as a percentage of normal, changed from 57.5% to 100.4% over the 12 months of GH administration. Mean power changed from 58.9% to 82.5% of normal.
The Scandinavian study 23 used computerized axial tomography (CT scan) of the thigh, taken at the middle of the femur, before and after GH administration to assess changes in muscle mass and fat mass. Thigh muscle area increased by 33% over the 1 y of GH administration, while thigh fat area decreased by 25%. Such changes in body composition would certainly go a long way towards explaining the ®nding of increased physical performance following GH administration, as assessed on a bicycle ergometer, previously described by Eiholzer and colleagues. 21 Extensive testing of physical strength and agility were carried out in the more recent US-based study. 24 The latter attribute was tested using a modi®ed Bruinites ± Oseretsky test, 25 in which the time taken to run and pick up a block and return was recorded. A standing broad jump was used to assess lower extremity strength, the number of sit-ups achieved in 20 s assessed trunk strength, and dumbbell weights were used to measure upper extremity strength. There were signi®cant improvements in all of these measures in the treated group. For example, upper strength as Prader±Willi Syndrome PSW Davies measured by the mean number of repetitions of dumbbell lifts changed from 13.1 to 15.6 in the treatment group but showed no such change in the control group (13.2 changing to 12.1). The authors concluded that to the children and families the most important result of GH therapy was improvement in physical abilities and exercise tolerance, and these were related to what was termed`real life' function Ð examples given include carrying large milk containers and independently climbing steps and stairs. It is noteworthy that the increase in linear growth also found in the study was not seen as the major improvement in the children's lives. If spontaneous physical activity also increases, as inferred by this study, inevitably total energy expenditure will increase which will improve the energy balance of the individual. This coupled with the increased resting metabolic rate associated with the increased lean body mass could begin to impact upon body composition in a bene®cial way. Bene®ts that might arise from GH administration as taken from the various studies reported are shown in Table 2 .
Effect of GH administration on behaviour
Disturbances in behaviour are one of the more challenging aspects of managing a child or young adult with PWS. It is therefore surprising perhaps that few data exist in the literature to document changes, be they positive or negative, on behaviour following the initiation and cessation of GH treatment. Most clinicians and scientists working with individuals with PWS and their families are, however, aware of anecdotal reports of changes in mood and behaviour during treatment with GH. One study 26 that evaluated changes in distinct aspects of behaviour, namely daytime somnolence, incidence of tempter tantrums, skin picking and night time sleep disturbances, found that these behavioural parameters did not change following the initiation of GH treatment. These data are supported by the experience of others 27 who report similar ®ndings. Of interest in this latter paper was the ®nding that, after stopping GH administration, the bad psychological features of PWS became`worst than ever', according to the parents of the children studied. Clearly more data are required in this area.
Risks and ethical issues
The use of GH in any condition is not without some risks. The level of risk, however, varies dramatically from local soreness at the site of injection of GH to the potential development of leukemia. 28 This latter concern is based primarily on the fact that by its very nature GH is mitogenic and consideration should be given to its possible role in promoting a benign or malignant tumour. However this is considered a remote risk. A more tangible risk is a disturbance in glucose homeostasis and the potential of a child or young adult with PWS to develop diabetes. GH produces physiological glucose intolerance and a high incidence of diabetes mellitus in children and young adults with PWS has been reported on a number of occasions. Undoubtedly the associated complications of diabetes mellitus, notably heart disease, renal failure, hypertension and microvascular disease add to the morbidity seen in the syndrome.
However, it has recently been reported 29 that patients with PWS do not show the same insulin resistance that can be demonstrated in obese individuals without PWS. Zipf concludes that the high incidence of diabetes mellitus in PWS is not a simple association with the level of obesity found in the syndrome and that a different physiological mechanism is in operation. The risk of diabetes mellitus occurring in children with PWS has also been reported by Lindgren and colleagues. 30 One out of 19 patients given GH over a 2 y period developed diabetes, however in the majority of patients fasting insulin levels remained within the normal range. This group recommends strongly that low doses of GH should be used in treating PWS and that glucose homeostasis should be closely monitored, especially if the patient is very obese. It is noteworthy that the same group reported elsewhere 31 that glucose homeostasis returned to normal in all cases when GH treatment was withdrawn.
In the ethical debate all risks should be weighed carefully against the potential bene®ts. Some bene®ts recorded thus far include an increase in height velocity (although there is no evidence to date that ®nal adult height will increase), a reduction or stabilization of body weight, and a bene®cial change in body composition which leads to improvements in functional capacity. Other considerations should relate to the length of treatment when treatment should commence. The work of Lindgren and Ritzen, 31 who have followed to date 18 children over a 5 y period, provides the best data available to answer the former question. This excellent longitudinal study suggests that long-term GH treatment seems to stabilize BMI provided that there is a continuation of a reduced calorie intake.
Only one paper 22 provides evidence that can be used to infer information relating to the timing of the onset of GH treatment. When multiple regression analysis was used to determine the in¯uencing factors on change in height SDS the most signi®cant variable was the child's age (P 0.06). This is in line with the response of IGHD children in whom the early onset of treatment yields the greatest degree of catch-up growth. This limited data might suggest, therefore, that early onset of treatment is desirable for at least the attainment of maximal height, although as has been stated elsewhere this may not be the most important physiological outcome of GH treatment in this syndrome.
In some countries GH is only available via the State on the basis of stature, ie the individual must be below the third or ®rst centile for height regardless of any other indication. It might be argued that the indication for GH use should be widened now that we are more fully aware of the effects of the hormone on body composition and functional capacity.
Treatment with GH is an expensive form of therapy and economic realities will also play a part in the debate. The idealists will argue that this should not enter the discussion but the realists will win that particular argument. In some there is a mindset that determines the success of any form of GH treatment based upon changes in linear growth. In the early days of GH treatment in the 1960s, primarily for isolated GH de®ciency, this might have been a valid philosophy. It may be that we have moved on since that time. It has been suggested that the increase in linear growth observed in children with PWS when given GH should be a minor player in considerations relating to GH therapy.
An excellent article 32 that discusses in depth the ethical issues associated with GH treatment in both Prader ± Willi and Down Syndromes concluded that preliminary data suggested that a medical bene®t was more likely to be demonstrated in PWS than Down Syndrome. The authors also concluded,`further well designed studies were needed to more fully evaluate the risks and bene®ts'. The studies described earlier in the text provide much of this data, certainly in relation to the bene®ts.
We may therefore now be in a position to respond to the editorial by Connor in 1993 with the conclusion that, while no virtue goes with size, there is a virtue in preventing or reducing the morbid obesity of the child with PWS and that the case for GH doing so is now being made.
